)
Edge14 Nov 2025
Ball: The King of Cans
From a 19th-century glass-jar legacy to a global plant network, Ball is now a pure-play aluminum can partner to the world's biggest beverage brands.
Aura Biosciences (AURA) investor relations material
Aura Biosciences Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Bel-sar is in late-stage clinical development for early choroidal melanoma, with additional trials in metastases to the choroid, bladder cancer, and ocular surface cancers; Phase 3 enrollment may complete in 2026, with topline data expected in Q4 2027.
Bel-sar demonstrated an 80% tumor control rate and 90% visual acuity preservation in Phase 2, with a favorable safety profile and new immune profiling data supporting its dual mechanism.
No product revenue has been generated to date; operations are funded through equity offerings, with $495.4 million raised since inception.
Net loss for the nine months ended September 30, 2025, was $80.6 million, up from $61.1 million in the prior year period; Q3 2025 net loss was $26.1 million.
Measures to improve Compass Phase 3 trial enrollment have increased the eligible patient pool to 280, with 90% of clinical sites activated.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $161.9 million as of September 30, 2025, sufficient to fund operations into the first half of 2027.
Research and development expenses rose to $68.4 million for the nine months ended September 30, 2025, and $22.2 million for Q3 2025, driven by clinical trial costs and personnel growth.
General and administrative expenses were $17.2 million for the nine months ended September 30, 2025, and $5.7 million for Q3 2025.
Net cash used in operating activities was $64.3 million for the nine months ended September 30, 2025.
Net loss per share was $(1.39) for the nine months ended September 30, 2025, and $0.40 for Q3 2025, with 65.9 million shares outstanding.
Outlook and guidance
Existing cash and marketable securities are expected to fund operations into the first half of 2027.
Compass Phase 3 trial enrollment expected to complete in 2026, with topline data for the 15-month endpoint in Q4 2027.
Phase 1b/2 NMIBC trial remains on track, with initial three-month clinical data expected mid-2026.
Early proof-of-concept data for metastases to the choroid and cancers of the ocular surface anticipated in 2026.
Substantial additional funding will be needed to complete bel-sar development and commercialization.
Assess impact of Compass trial enrollment measures
How does bel-sar's NMIBC immune data differentiate it?
Evaluate bel-sar's expanded ocular oncology strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aura Biosciences earnings date
Q4 202520 Mar, 2026
Next Aura Biosciences earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aura Biosciences Inc. is a biotechnology company focused on developing therapies for cancer treatment. It specializes in the creation of virus-like drug conjugates (VDC) technology, aiming to address tumors with significant unmet medical needs in ocular and urologic oncology. A key development in their portfolio is AU-011, a VDC candidate targeting primary choroidal melanoma. The company also explores the potential of AU-011 for other ocular oncology indications, including choroidal metastases, and is conducting Phase 2 dose-escalation trials. Aura Biosciences is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage